Chapter 1 Myasthenia Gravis Drugs Market Overview
1.1 Myasthenia Gravis Drugs Definition
1.2 Global Myasthenia Gravis Drugs Market Size Status and Outlook (2015-2030)
1.3 Global Myasthenia Gravis Drugs Market Size Comparison by Region (2015-2030)
1.4 Global Myasthenia Gravis Drugs Market Size Comparison by Type (2015-2030)
1.5 Global Myasthenia Gravis Drugs Market Size Comparison by Application (2015-2030)
1.6 Global Myasthenia Gravis Drugs Market Size Comparison by Sales Channel (2015-2030)
1.7 Myasthenia Gravis Drugs Market Dynamics (COVID-19 Impacts)
1.7.1 Market Drivers/Opportunities
1.7.2 Market Challenges/Risks
1.7.3 Market News (Mergers/Acquisitions/Expansion)
1.7.4 COVID-19 Impacts on Current Market
1.7.5 Post-Strategies of COVID-19 Outbreak
Chapter 2 Myasthenia Gravis Drugs Market Segment Analysis by Player
2.1 Global Myasthenia Gravis Drugs Sales and Market Share by Player (2018-2020)
2.2 Global Myasthenia Gravis Drugs Revenue and Market Share by Player (2018-2020)
2.3 Global Myasthenia Gravis Drugs Average Price by Player (2018-2020)
2.4 Players Competition Situation & Trends
2.5 Conclusion of Segment by Player
Chapter 3 Myasthenia Gravis Drugs Market Segment Analysis by Type
3.1 Global Myasthenia Gravis Drugs Market by Type
3.1.1 Surgery
3.1.2 Medication
3.1.3 Plasmapheresis and Intravenous Immunoglobulin
3.1.4 Autologous Hematopoietic Stem Cell Transplantation
3.1.5 Other
3.2 Global Myasthenia Gravis Drugs Sales and Market Share by Type (2015-2020)
3.3 Global Myasthenia Gravis Drugs Revenue and Market Share by Type (2015-2020)
3.4 Global Myasthenia Gravis Drugs Average Price by Type (2015-2020)
3.5 Leading Players of Myasthenia Gravis Drugs by Type in 2020
3.6 Conclusion of Segment by Type
Chapter 4 Myasthenia Gravis Drugs Market Segment Analysis by Application
4.1 Global Myasthenia Gravis Drugs Market by Application
4.1.1 Hospitals
4.1.2 Academic Research Institutes
4.1.3 Clinics
4.1.4 Other
4.2 Global Myasthenia Gravis Drugs Revenue and Market Share by Application (2015-2020)
4.3 Leading Consumers of Myasthenia Gravis Drugs by Application in 2020
4.4 Conclusion of Segment by Application
Chapter 5 Myasthenia Gravis Drugs Market Segment Analysis by Sales Channel
5.1 Global Myasthenia Gravis Drugs Market by Sales Channel
5.1.1 Direct Channel
5.1.2 Distribution Channel
5.2 Global Myasthenia Gravis Drugs Revenue and Market Share by Sales Channel (2015-2020)
5.3 Leading Distributors/Dealers of Myasthenia Gravis Drugs by Sales Channel in 2020
5.4 Conclusion of Segment by Sales Channel
Chapter 6 Myasthenia Gravis Drugs Market Segment Analysis by Region
6.1 Global Myasthenia Gravis Drugs Market Size and CAGR by Region (2015-2030)
6.2 Global Myasthenia Gravis Drugs Sales and Market Share by Region (2015-2020)
6.3 Global Myasthenia Gravis Drugs Revenue and Market Share by Region (2015-2020)
6.4 North America
6.4.1 North America Market by Country
6.4.2 North America Myasthenia Gravis Drugs Market Share by Type
6.4.3 North America Myasthenia Gravis Drugs Market Share by Application
6.4.4 United States
6.4.5 Canada
6.4.6 Mexico
6.5 Europe
6.5.1 Europe Market by Country
6.5.2 Europe Myasthenia Gravis Drugs Market Share by Type
6.5.3 Europe Myasthenia Gravis Drugs Market Share by Application
6.5.4 Germany
6.5.5 UK
6.5.6 France
6.5.7 Italy
6.5.8 Russia
6.5.9 Spain
6.6 Asia-Pacific
6.6.1 Asia-Pacific Market by Country
6.6.2 Asia-Pacific Myasthenia Gravis Drugs Market Share by Type
6.6.3 Asia-Pacific Myasthenia Gravis Drugs Market Share by Application
6.6.4 China
6.6.5 Japan
6.6.6 Korea
6.6.7 India
6.6.8 Southeast Asia
6.6.9 Australia
6.7 South America
6.7.1 South America Market by Country
6.7.2 South America Myasthenia Gravis Drugs Market Share by Type
6.7.3 South America Myasthenia Gravis Drugs Market Share by Application
6.7.4 Brazil
6.7.5 Argentina
6.7.6 Colombia
6.8 Middle East & Africa
6.8.1 Middle East & Africa Market by Country
6.8.2 Middle East & Africa Myasthenia Gravis Drugs Market Share by Type
6.8.3 Middle East & Africa Myasthenia Gravis Drugs Market Share by Application
6.8.4 UAE
6.8.5 Saudi Arabia
6.8.6 South Africa
6.9 Conclusion of Segment by Region
Chapter 7 Profile of Leading Myasthenia Gravis Drugs Players
7.1 AbbVie
7.1.1 Company Snapshot
7.1.2 Product/Service Offered
7.1.3 Business Performance (Sales, Price, Revenue, Gross Margin and Market Share)
7.1.4 COVID-19 Impact on AbbVie
7.2 Alexion Pharmaceuticals
7.3 Avadel Pharmaceuticals
7.4 Bausch Health
7.5 Baxter International
7.6 Biogen
7.7 Bristol-Myers Squibb
7.8 Catalyst Pharmaceuticals
7.9 Cipla
7.10 CSL
7.11 Curavac
7.12 Cytokinetics
7.13 Flamel Technologies
7.14 Fresenius Kabi
7.15 Galencia
7.16 GlaxoSmithKline
7.17 Grifols
7.18 Lupin Pharmaceuticals
7.19 Mitsubishi Tanabe Pharma
7.20 Novartis
7.21 Pfizer
7.22 Piramal Healthcare
7.23 Roche
7.24 RPG Life Sciences
7.25 Sun Pharmaceuticals
7.26 Takeda Pharmaceutical
7.27 Teva Pharmaceutical
7.28 Valeant Pharmaceuticals
Chapter 8 Upstream and Downstream Analysis of Myasthenia Gravis Drugs
8.1 Industrial Chain of Myasthenia Gravis Drugs
8.2 Upstream of Myasthenia Gravis Drugs
8.2.1 Raw Materials
8.2.2 Labor Cost
8.2.3 Manufacturing Expenses
8.2.4 Manufacturing Cost Structure
8.2.5 Manufacturing Process
8.3 Downstream of Myasthenia Gravis Drugs
8.3.1 Leading Distributors/Dealers of Myasthenia Gravis Drugs
8.3.2 Leading Consumers of Myasthenia Gravis Drugs
Chapter 9 Development Trend of Myasthenia Gravis Drugs (2021-2030)
9.1 Global Myasthenia Gravis Drugs Market Size (Sales and Revenue) Forecast (2021-2030)
9.2 Global Myasthenia Gravis Drugs Market Size and CAGR Forecast by Region (2021-2030)
9.3 Global Myasthenia Gravis Drugs Market Size and CAGR Forecast by Type (2021-2030)
9.4 Global Myasthenia Gravis Drugs Market Size and CAGR Forecast by Application (2021-2030)
9.5 Global Myasthenia Gravis Drugs Market Size and CAGR Forecast by Sales Channel (2021-2030)
Chapter 10 Appendix
10.1 Research Methodology
10.2 Data Sources
10.3 Disclaimer
10.4 Analysts Certification
